Genentech is a US biotechnology company and subsidiary of Roche, focused on neuroscience research and drug development. Founded in 1976 in South San Francisco, California, Genentech pioneered the recombinant DNA technology era and has become one of the world's leading biotechnology companies. Since its acquisition by Roche in 2009 for approximately 7 billion, Genentech operates as an independent subsidiary while leveraging Roche's global resources and pipeline infrastructure[1].
| Attribute | Value |
|---|---|
| Parent Company | Roche |
| Founded | 1976 |
| Headquarters | South San Francisco, CA |
| CEO | Thomas Schinecker |
| Employees | ~13,000 |
| Revenue (2023) | ~$7.5 billion |
Genentech has a long history in Alzheimer's disease research, with multiple programs targeting amyloid-beta and tau pathology. Their neuroscience division focuses on understanding disease mechanisms and developing disease-modifying therapies[2].
Crenezumab is an anti-amyloid-beta monoclonal antibody developed in partnership with AC Immune. Unlike other anti-Aβ antibodies, crenezumab targets both monomers and oligomers of Aβ, potentially providing broader pathological coverage[3].
Gantenerumab is a fully human monoclonal antibody that binds to Aβ plaques and promotes their removal via microglia-mediated phagocytosis[4].
Genentech and Roche have an active preclinical LRRK2 inhibitor program in collaboration with Vanqua Bio. The lead compound from this partnership is G007-LK, a potent, selective, and brain-penetrant small molecule LRRK2 kinase inhibitor.
| Attribute | Value |
|---|---|
| Lead Compound | G007-LK |
| Target | LRRK2 (leucine-rich repeat kinase 2) |
| Indication | Parkinson's disease (LRRK2 mutation carriers) |
| Stage | Preclinical / IND-enabling |
| Route | Oral |
| Collaboration | Vanqua Bio (joint development) |
G007-LK Design:
100-fold selectivity over related kinases
Preclinical Profile:
G007-LK competes in the LRRK2 inhibitor landscape alongside BIIB122 (Biogen/Denali, Phase 2b) and NEU-411 (Neuron23, Phase 2). The collaboration with Vanqua Bio provides Genentech with a differentiated, highly selective LRRK2 inhibitor for the treatment of Parkinson's disease[5].
For more detail, see G007-LK LRRK2 Inhibitor.
Genentech's neuroscience pipeline includes earlier-stage programs targeting:
Genentech maintains a strategic partnership with AC Immune SA for the development of anti-amyloid and anti-tau therapeutics. This collaboration has generated multiple clinical candidates including crenezumab and ACI-35 (tau vaccine)[6].
As part of Roche's broader neuroscience efforts, Genentech contributes to:
Genentech has been a strong proponent of the amyloid cascade hypothesis, believing that early intervention with amyloid-targeting therapies may prevent or slow disease progression. Their clinical trial programs have helped advance understanding of:
Beyond amyloid, Genentech investigates tau protein pathology as a key driver of neurodegeneration. Tau-targeted programs include:
Garvier et al. Discovery of G007-LK: A potent, selective, brain-penetrant LRRK2 kinase inhibitor. J Med Chem. 2022. ↩︎